PDF
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW.
Today, February 20, 2024, is the last day of trading with the warrants of series TO3 in Pharmacolog i Uppsala AB ("Pharmacolog" or the "Company"). The exercise period for the warrants of series TO3 continues until February 23, 2024. Each warrant of series TO3 entitles the holder to subscribe for one (1) new series B share in Pharmacolog to an exercise price of SEK 0.054 per share.
If all warrants of series TO3 are exercised, the Company will receive approximately SEK 2.5 million before issue costs. In order for the options not to expire without value, the holder must actively subscribe for shares no later than February 23, 2024, or alternatively sell the warrants no later than February 20, 2024. Please note that some nominees may close their subscriptions earlier than February 23, 2024.
Summarized terms for the warrants of series TO3:
Exercise period: February 9, 2024 - February 23, 2024.
Issue volume: 46,739,208 warrants of series TO3 entitle the subscription of 46,739,208 series B shares. At full exercise, the Company receives approximately SEK 2.5 million before issue costs.
Subscription price: SEK 0.054 per share.
Last day of trading with warrants of series TO3: February 20, 2024.
Share capital and dilution: At full exercise of the warrants of series TO3, the share capital increases by SEK 467,392.08, from SEK 662,503.42 to SEK 1,129,895.50. The number of shares increases at full exercise by 46,739,208 series B shares, from 66,250,342 to 112,989,550. Dilution at full exercise amounts to approximately 41.37 percent of the existing number of shares and votes in the Company.
Please be advised: The invested amount must be rounded up to two decimal places.
Please note that the warrants not exercised by February 23, 2024, or disposed no later than February 20, 2024, will expire worthless. To prevent the expiration of the warrants, active subscription of shares or disposal of the warrants is required.
How the warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrant shall be made in accordance with instructions from the respective nominee. Please contact your nominee for further information.
Direct-registered Warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration by the Swedish Companies Registration Office.
Advisors
Mangold Fondkommission AB is the financial advisor to Pharmacolog in connection with the exercise of the warrants. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants.